Annovis Bio
ANVS
32 hedge funds and large institutions have $14.4M invested in Annovis Bio in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 10 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
0.31% less ownership
Funds ownership: 11.74% → 11.43% (-0.31%)
11% less funds holding
Funds holding: 36 → 32 (-4)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
36% less capital invested
Capital invested by funds: $22.5M → $14.4M (-$8.12M)
51% less call options, than puts
Call options by funds: $12.4M | Put options by funds: $25.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$620K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$225K |
| 3 |
CS
Cannell & Spears
New York
|
+$164K |
| 4 |
LIG
Lokken Investment Group
Lewes,
Delaware
|
+$134K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$609K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$386K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$230K |
| 4 |
Jane Street
New York
|
-$224K |
| 5 |
Citigroup
New York
|
-$209K |
ANVS Hedge Fund Activity: Q1 2024 in Review
32 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q1 2024, worth a combined $14.4M — down 36% from $22.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ANVS and 7 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 12 added.
The largest buyer was Susquehanna International Group, adding an estimated $620K. The largest seller was Marshall Wace, exiting entirely with an estimated $609K sold.
- 32 institutional investors held Annovis Bio (ANVS) as of Q1 2024, down from 36 in Q4 2023.
- Funds reported $14.4M of Annovis Bio stock for Q1 2024, down 36% quarter-over-quarter.
- 7 funds opened new Annovis Bio positions in Q1 2024 and 10 closed out, a net change of -3 holders.
- The largest Annovis Bio buyer in Q1 2024 was Susquehanna International Group, an estimated $620K added.
- The largest Annovis Bio seller in Q1 2024 was Marshall Wace, an estimated $609K sold.
Based on aggregated 13F filings for Q1 2024.